Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Galvus

    Tag: galvus

    You Searched For "Galvus"
    Morepen Labs adds blockbuster Rivaroxaban, Vildagliptin, UDCA to API portfolio

    Morepen Labs adds blockbuster Rivaroxaban, Vildagliptin, UDCA to API portfolio

    Farhat Nasim14 Oct 2019 1:36 PM IST
    While two products Rivaroxaban and Vildagliptin will augment Morepen Lab's presence in the cardiac and diabetic segments respectively, the third...
    Fight for Vildagliptin: Natco goes to court against Novartis

    Fight for Vildagliptin: Natco goes to court against Novartis

    Farhat Nasim7 Sept 2019 4:32 PM IST
    Mumbai: Throwing an indirect challenge at patent holder Novartis, drugmaker Natco Pharma has submitted a fresh application in a Hyderabad court...
    4 Pharma Giants face price fixing allegations on Vidagliptin: CCI starts probe

    4 Pharma Giants face price fixing allegations on Vidagliptin: CCI starts probe

    Ruby Khatun Khatun15 Dec 2017 5:15 PM IST
    Mumbai: Trouble is mounting for 4 big pharma companies over price fixing of an anti-diabetic drug. An investigation has initiated on drug makers...
    Novartis, Abbott, Emcure face allegations of cartelisation in anti-diabetes drug Vildagliptin

    Novartis, Abbott, Emcure face allegations of cartelisation in anti-diabetes drug Vildagliptin

    savita thakur thakur26 March 2017 11:33 AM IST
    The Swiss drug maker Novartis and US based Abbott along with domestic companies Emcure and USV Pharma are under the lens of Health Ministry and...

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok